BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23069925)

  • 1. Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer.
    Schroeder RP; De Blois E; De Ridder CM; Van Weerden WM; Breeman WA; de Jong M
    Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):468-75. PubMed ID: 23069925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.
    Schroeder RP; van Weerden WM; Krenning EP; Bangma CH; Berndsen S; Grievink-de Ligt CH; Groen HC; Reneman S; de Blois E; Breeman WA; de Jong M
    Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1257-66. PubMed ID: 21431398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of a novel ¹¹¹In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer.
    Carlucci G; Ananias HJ; Yu Z; Hoving HD; Helfrich W; Dierckx RA; Liu S; de Jong IJ; Elsinga PH
    Mol Pharm; 2013 May; 10(5):1716-24. PubMed ID: 23590837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
    Schroeder RP; de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Breeman WA; Krenning EP; de Jong M
    Int J Cancer; 2010 Jun; 126(12):2826-34. PubMed ID: 19876914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer.
    Zhang X; Cai W; Cao F; Schreibmann E; Wu Y; Wu JC; Xing L; Chen X
    J Nucl Med; 2006 Mar; 47(3):492-501. PubMed ID: 16513619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice.
    Ho CL; Chen LC; Lee WC; Chiu SP; Hsu WC; Wu YH; Yeh CH; Stabin MG; Jan ML; Lin WJ; Lee TW; Chang CH
    Cancer Biother Radiopharm; 2009 Aug; 24(4):435-43. PubMed ID: 19694578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues.
    Schroeder RP; Müller C; Reneman S; Melis ML; Breeman WA; de Blois E; Bangma CH; Krenning EP; van Weerden WM; de Jong M
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1386-96. PubMed ID: 20182713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides.
    Mansi R; Wang X; Forrer F; Kneifel S; Tamma ML; Waser B; Cescato R; Reubi JC; Maecke HR
    Clin Cancer Res; 2009 Aug; 15(16):5240-9. PubMed ID: 19671861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
    Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
    J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors.
    Honer M; Mu L; Stellfeld T; Graham K; Martic M; Fischer CR; Lehmann L; Schubiger PA; Ametamey SM; Dinkelborg L; Srinivasan A; Borkowski S
    J Nucl Med; 2011 Feb; 52(2):270-8. PubMed ID: 21233180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
    Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
    Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of the new GRPR-antagonist
    Lymperis E; Kaloudi A; Kanellopoulos P; Krenning EP; de Jong M; Maina T; Nock BA
    J Labelled Comp Radiopharm; 2019 Aug; 62(10):646-655. PubMed ID: 30963606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
    Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
    J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs.
    Carlucci G; Kuipers A; Ananias HJ; de Paula Faria D; Dierckx RA; Helfrich W; Rink R; Moll GN; de Jong IJ; Elsinga PH
    Peptides; 2015 May; 67():45-54. PubMed ID: 25797109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [
    Kálmán-Szabó I; Szabó JP; Arató V; Dénes N; Opposits G; Jószai I; Kertész I; Képes Z; Fekete A; Szikra D; Hajdu I; Trencsényi G
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue.
    Rogers BE; Bigott HM; McCarthy DW; Della Manna D; Kim J; Sharp TL; Welch MJ
    Bioconjug Chem; 2003; 14(4):756-63. PubMed ID: 12862428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and evaluation of 99mTc-EDDA/HYNIC-[Lys 3]-bombesin for imaging gastrin-releasing peptide receptor-positive tumours.
    Ferro-Flores G; Arteaga de Murphy C; Rodriguez-Cortés J; Pedraza-López M; Ramírez-Iglesias MT
    Nucl Med Commun; 2006 Apr; 27(4):371-6. PubMed ID: 16531924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
    Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
    Zhang H; Chen J; Waldherr C; Hinni K; Waser B; Reubi JC; Maecke HR
    Cancer Res; 2004 Sep; 64(18):6707-15. PubMed ID: 15374988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.